1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,139 | 0,160 | 07:14 | |
| 0,139 | 0,160 | 07:08 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 04:46 | SinoMab BioScience Limited: Dr. Shui On Leung Invited to the 2026 LifeArc Translational Science Summit in the UK | 290 | JCN Newswire | HONG KONG, May 13, 2026 - (ACN Newswire) - SinoMab BioScience Limited ('SinoMab' or the 'Company', together with its subsidiaries, the 'Group' stock code: 03681.HK) is pleased to announce that Dr. Shui... ► Artikel lesen | |
| 27.04. | SINOMAB BIO-B (03681): 2025 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT | 2 | HKEx | ||
| 27.04. | SINOMAB BIO-B (03681): NOTIFICATION LETTER TO NON-REGISTERED SHAREHOLDERS AND REPLY FORM | 1 | HKEx | ||
| 27.04. | SINOMAB BIO-B (03681): NOTIFICATION LETTER TO REGISTERED SHAREHOLDERS AND REPLY FORM | - | HKEx | ||
| 27.04. | SINOMAB BIO-B (03681): NOTICE OF 2026 ANNUAL GENERAL MEETING | 1 | HKEx | ||
| 27.04. | SINOMAB BIO-B (03681): FORM OF PROXY FOR THE ANNUAL GENERAL MEETING TO BE HELD AT ROOM 3, 14/F, FAIRMONT HOUSE, 8 COTTON TREE DRIVE, CENTRAL, HONG KONG ... | 1 | HKEx | ||
| SINOMAB BIOSCIENCE Aktie jetzt für 0€ handeln | |||||
| 27.04. | SINOMAB BIO-B (03681): PROPOSED RE-ELECTION OF RETIRING DIRECTORS, PROPOSED ELECTION OF A DIRECTOR AND PROPOSED GRANTING OF GENERAL MANDATES TO BUY BACK ... | - | HKEx | ||
| 27.04. | SINOMAB BIO-B (03681): ANNUAL REPORT 2025 | 1 | HKEx | ||
| 01.04. | SINOMAB BIO-B (03681): VOLUNTARY ANNOUNCEMENT FIRST PATIENT DOSED IN PHASE 2 CLINICAL TRIAL OF SM17 FOR ATOPIC DERMATITIS IN CHINA | - | HKEx | ||
| 31.03. | SINOMAB BIO-B (03681): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS | - | HKEx | ||
| 31.03. | SINOMAB BIO-B (03681): RESIGNATION OF NON-EXECUTIVE DIRECTORS | - | HKEx | ||
| 25.03. | SINOMAB BIO-B (03681): VOLUNTARY ANNOUNCEMENT TOPLINE RESULTS FROM PHASE 1 BRIDGING STUDY FOR ROUTE OF ADMINISTRATION CONVERSION OF SM17 IN CHINA | - | HKEx | ||
| 24.03. | SINOMAB BIO-B (03681): GRANT OF SHARE OPTIONS | - | HKEx | ||
| 24.03. | SinoMab BioScience Limited: SinoMab (03681.HK) Achieves Approximately 43.3% Year-over-Year Decrease in Annual Losses for 2025, Marking Significant Progress in Pipeline Advancement | 365 | JCN Newswire | HONG KONG, Mar 24, 2026 - (ACN Newswire) - SinoMab BioScience Limited ('SinoMab' or the 'Company', together with its subsidiaries, the 'Group' stock code: 03681.HK) is pleased to announce its annual... ► Artikel lesen | |
| 23.03. | SINOMAB BIO-B (03681): ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2025; AND CHANGE IN USE OF PROCEEDS | 2 | HKEx | ||
| 12.03. | SINOMAB BIO-B (03681): CONNECTED TRANSACTION - TERMINATION OF LEASE AGREEMENT | - | HKEx | ||
| 10.03. | SINOMAB BIO-B (03681): DATE OF BOARD MEETING | - | HKEx | ||
| 24.02. | SINOMAB BIO-B (03681): VOLUNTARY ANNOUNCEMENT IND APPROVAL FOR IBD OF SM17 BY NMPA | - | HKEx | ||
| 18.02. | XFRA NEW INSTRUMENTS AVAILABLE ON 18.02.2026 | 1.442 | Xetra Newsboard | The following instruments on XETRA do have their first trading 18.02.2026 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 18.02.2026
Aktien
1 US02083X2027 Alpine Income Property... ► Artikel lesen | |
| 11.12.25 | SINOMAB BIO-B (03681): VOLUNTARY ANNOUNCEMENT IND APPLICATION FOR SM17 ACCEPTED BY NMPA CDE | - | HKEx |
20 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 28,800 | +2,27 % | Qiagen erhöht Dividende und stellt weitere Aktienrückkäufe in Aussicht | DJ Qiagen erhöht Dividende und stellt weitere Aktienrückkäufe in Aussicht
DOW JONES--Die Aktionäre von Qiagen können sich über eine höhere Dividende freuen. Wie es in der Einladung zur Hauptversammlung... ► Artikel lesen | |
| INHIBRX BIOSCIENCES | 109,03 | +0,35 % | Inhibrx Biosciences, Inc.: Inhibrx Reports Interim Phase 2 Data for INBRX-106 in First-Line HNSCC; Initial Results Demonstrate Potential Costimulatory Benefit Over PD-1 Monotherapy | Interim analyses show INBRX-106 + pembrolizumab achieved a 44.0% confirmed Objective Response Rate (cORR): In the preliminary confirmed response-evaluable population... ► Artikel lesen | |
| ERNEXA THERAPEUTICS | 12,150 | +1,17 % | Ernexa Therapeutics Inc.: Ernexa Therapeutics Unveils Breakthrough Preclinical Results: ERNA-101 Achieves 100% Survival and Complete Tumor Elimination in Ovarian Cancer Models | CAMBRIDGE, Mass., May 06, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 343,62 | +0,12 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2026 Financial Results | FDA accepted the new drug application (NDA) for ulixacaltamide in Essential Tremor with a PDUFA target action date of January 29, 2027, and the NDA for relutrigine, with priority review, in SCN2A... ► Artikel lesen | |
| MODERNA | 45,405 | +0,09 % | Moderna: Hantavirus-Schlagzeilen treiben Impfstoff-Aktie an | Das Hantavirus ist auf einem kleinen Kreuzfahrtschiff im Atlantik ausgebrochen. Die Weltgesundheitsorganisation (WHO) hat inzwischen fünf von acht Verdachtsfällen als offizielle Fälle bestätigt. Aus... ► Artikel lesen | |
| CG ONCOLOGY | 72,05 | -0,03 % | CG Oncology Inc.: CG Oncology Reports First Quarter 2026 Financial Results and Provides Business Updates | Following alignment discussions with FDA, BLA completion for HR BCG-unresponsive NMIBC is expected fourth quarter 2026 PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy as an adjuvant... ► Artikel lesen | |
| ADMA BIOLOGICS | 8,400 | -0,12 % | Kehoe Law Firm, P.C.: ADMA Biologics Stock Alert (ADMA) - Kehoe Law Firm, P.C. Investigating Potential Securities Claims on Behalf of ADMA Biologics Investors | Philadelphia, Pennsylvania--(Newsfile Corp. - May 7, 2026) - Kehoe Law Firm, P.C. is investigating potential securities claims on behalf of investors of ADMA Biologics, Inc. ("ADMA Biologics" or... ► Artikel lesen | |
| CULLINAN THERAPEUTICS | 16,140 | -0,06 % | CGEM Forum Reveals Only 6,000 Moroccan Firms Export, a Path to Change chartered | ||
| ARCUTIS BIOTHERAPEUTICS | 20,700 | +0,05 % | Arcutis Q1 2026: Umsatz steigt um 65 %, doch Expansionskosten führen zu höheren Verlusten | ||
| BIONTECH | 79,70 | -0,13 % | Alarm bei BioNTech! Milliarden bei Hensoldt! Kaufchance bei North Arrow Minerals! | "Erst kaufen, dann killen", so reagierte Tübingens Oberbürgermeister Boris Palmer auf die geplanten Standortschließungen von BioNTech. Denn in diesem Rahmen sollen praktisch alle Standorte der erst... ► Artikel lesen | |
| ERASCA | 10,390 | +0,10 % | Erasca, Inc.: Erasca Reports First Quarter 2026 Business Updates and Financial Results | Robust monotherapy efficacy and generally well-tolerated safety results observed during dose escalation for ERAS-0015 in both KRAS G12X NSCLC and PDAC reinforce best-in-class potential across RAS-targeted... ► Artikel lesen | |
| EVOTEC | 5,080 | -2,31 % | EQS-News: Evotec SE: Evotec gibt Ergebnisse für das erste Quartal 2026 bekannt: Transformation gewinnt an Dynamik | EQS-News: Evotec SE
/ Schlagwort(e): Quartalsergebnis/Quartals-/Zwischenmitteilung
Evotec gibt Ergebnisse für das erste Quartal 2026 bekannt: Transformation gewinnt an Dynamik... ► Artikel lesen | |
| NUVALENT | 102,64 | +0,10 % | Nuvalent, Inc.: Nuvalent Highlights Recent Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports First Quarter 2026 Financial Results | NDA submitted for neladalkib in TKI pre-treated advanced ALK-positive NSCLC
NDA for zidesamtinib in TKI pre-treated advanced ROS1-positive NSCLC under FDA review... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 18,960 | +0,05 % | H.C. Wainwright cuts Summit Therapeutics stock price target on trial risk | ||
| COGENT BIOSCIENCES | 34,530 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Multiple Presentations at the European Hematology Association (EHA) 2026 Congress |
SINOMAB BIOSCIENCE LTD gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 0,144 Euro und damit -0,69 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SINOMAB BIOSCIENCE LTD finden Sie auf Wallstreet Online.